Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Ginsberg

Showing results (21-30 of 39) with videos related to

Pageof 4
Sort By:
BJU International|July 6, 2013
Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladderDavid Ginsberg, Tim Schneider, Con Kelleher, et al.
Bioelectronic Medicine|March 23, 2022
Noninvasive spinal neuromodulation mitigates symptoms of idiopathic overactive bladderHui Zhong, Emilie Liu, Priya Kohli, et al.
BJU International|February 18, 2014
Impact of urinary incontinence on healthcare resource utilization, health-related quality of life and productivity in patients with overactive bladderDerek H Tang, Danielle C Colayco, Kristin M Khalaf, et al.
Journal of Neurotrauma|July 27, 2023
Resilience as an Independent Predictor of Bowel Related Quality of Life After Spinal Cord InjuryAidin Abedi, Stefania Montero, Luis Morales Ojeda, et al.
Neurourology and Urodynamics|May 11, 2023
Content, face, and construct validity of the Irritable Bowel Syndrome Quality of Life (IBS-QOL) as a measure of bowel-related quality of life in spinal cord injuryAidin Abedi, Priya Kohli, Stefania Montero, et al.
The Journal of Urology|April 17, 2012
Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivityDavid Ginsberg, Angelo Gousse, Veronique Keppenne, et al.
The Journal of Urology|April 4, 2016
Durable Efficacy and Safety of Long-Term OnabotulinumtoxinA Treatment in Patients with Overactive Bladder Syndrome: Final Results of a 3.5-Year StudyVictor W Nitti, David Ginsberg, Karl-Dietrich Sievert, et al.
European Urology|April 3, 2012
OnabotulinumtoxinA improves health-related quality of life in patients with urinary incontinence due to idiopathic overactive bladder: a 36-week, double-blind, placebo-controlled, randomized, dose-ranging trialClare J Fowler, Stephen Auerbach, David Ginsberg, et al.
Journal of Plastic, Reconstructive & Aesthetic Surgery : JPRAS|December 30, 2017
Surviving Fournier's gangrene: Multivariable analysis and a novel scoring system to predict length of staySaum B Ghodoussipour, Daniel Gould, Jacob Lifton, et al.
Journal of the American Academy of Dermatology|April 6, 2021
Bridging the digital divide: The use of text message-enabled video in the public safety-net settingAbigail Cline, Carey Kim, Juliana Berk-Krauss, et al.
Pageof 4

Showing results (21-30 of 39) with videos related to

Sort By:
Pageof 4
BJU International|July 6, 2013
Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladderDavid Ginsberg, Tim Schneider, Con Kelleher, et al.
Bioelectronic Medicine|March 23, 2022
Noninvasive spinal neuromodulation mitigates symptoms of idiopathic overactive bladderHui Zhong, Emilie Liu, Priya Kohli, et al.
BJU International|February 18, 2014
Impact of urinary incontinence on healthcare resource utilization, health-related quality of life and productivity in patients with overactive bladderDerek H Tang, Danielle C Colayco, Kristin M Khalaf, et al.
Journal of Neurotrauma|July 27, 2023
Resilience as an Independent Predictor of Bowel Related Quality of Life After Spinal Cord InjuryAidin Abedi, Stefania Montero, Luis Morales Ojeda, et al.
Neurourology and Urodynamics|May 11, 2023
Content, face, and construct validity of the Irritable Bowel Syndrome Quality of Life (IBS-QOL) as a measure of bowel-related quality of life in spinal cord injuryAidin Abedi, Priya Kohli, Stefania Montero, et al.
The Journal of Urology|April 17, 2012
Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivityDavid Ginsberg, Angelo Gousse, Veronique Keppenne, et al.
The Journal of Urology|April 4, 2016
Durable Efficacy and Safety of Long-Term OnabotulinumtoxinA Treatment in Patients with Overactive Bladder Syndrome: Final Results of a 3.5-Year StudyVictor W Nitti, David Ginsberg, Karl-Dietrich Sievert, et al.
European Urology|April 3, 2012
OnabotulinumtoxinA improves health-related quality of life in patients with urinary incontinence due to idiopathic overactive bladder: a 36-week, double-blind, placebo-controlled, randomized, dose-ranging trialClare J Fowler, Stephen Auerbach, David Ginsberg, et al.
Journal of Plastic, Reconstructive & Aesthetic Surgery : JPRAS|December 30, 2017
Surviving Fournier's gangrene: Multivariable analysis and a novel scoring system to predict length of staySaum B Ghodoussipour, Daniel Gould, Jacob Lifton, et al.
Journal of the American Academy of Dermatology|April 6, 2021
Bridging the digital divide: The use of text message-enabled video in the public safety-net settingAbigail Cline, Carey Kim, Juliana Berk-Krauss, et al.
Pageof 4